MA-WOLTERS-KLUWER-HEALTH
17.11.2022 20:01:35 CET | Business Wire | Press release
Wolters Kluwer Health and NEJM Group have entered into an exclusive partnership to ensure that more researchers and clinicians around the world can access the growing family of NEJM Group journals. Building on years of collaboration, this expanded partnership positions NEJM Group journals for sustained global growth through Wolters Kluwer’s Ovid® medical research platform. Publications currently included are the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst Innovations in Care Delivery, NEJM Journal Watch, the NEJM Archive, and future NEJM Group journals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005838/en/
Wolters Kluwer Health will serve as the exclusive digital distributor of subscriptions to the New England Journal of Medicine, NEJM Evidence, NEJM Catalyst and NEJM Journal Watch (Graphic: Business Wire)
Unparalleled distribution critical to global reach
“The mission of NEJM Group is to advance medical knowledge from research to patient care, making the connections between developments in clinical science and clinical practice to improve healthcare quality and patient outcomes worldwide,” said David Sampson, Vice President of NEJM Group. “Wolters Kluwer’s worldwide sales and marketing presence creates additional opportunities to expand the reach of our content by delivering the NEJM Group portfolio of products to institutions globally.”
Through the partnership, institutional online subscribers to NEJM Group journals will be able to access their subscriber content both on NEJM Group sites and on the Ovid® medical research platform. Spanning over 150 publishers and more than 100 specialty areas, Ovid serves as the powerful, one-stop research software to help researchers, librarians, clinicians, and other healthcare professionals find timely and relevant medical information to make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. With the addition of NEJM Group titles, Ovid users will be able to search and access the best research and information at the intersection of biomedical science and clinical practice, supporting improved patient care and clinical outcomes.
“The New England Journal of Medicine is one of the most highly respected and impactful medical periodicals in the world, drawing on a rich history, and cited more than any other journal,” said Vikram Savkar, Senior Vice President & General Manager, Medicine Segment, Health Learning, Research & Practice at Wolters Kluwer. “Leveraging Ovid’s market-leading search technology alongside Wolters Kluwer’s global sales and marketing reach will ensure more access to NEJM Group journals and archives around the world. Bringing together NEJM Group and Wolters Kluwer creates a global research powerhouse for clinicians seeking answers to care questions and researchers pursuing the next great discovery.”
The partnership builds on a strong foundation that has been fortified over many years of collaboration and a shared vision for the future of healthcare. Both NEJM Group and Wolters Kluwer maintain the highest standards for curation and peer review, and both support increased access to data and research globally. NEJM Group content around matters of public health importance, such as Covid-19, will continue to be available for free.
NEJM Group publications that will be distributed to institutions via Wolters Kluwer include:
- The New England Journal of Medicine, recognized as the world’s leading medical journal, delivering high-quality, peer-reviewed research and interactive clinical content to physicians, educators, researchers, and the global medical community.
- NEJM Evidence, which presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
- NEJM Catalyst Innovations in Care Delivery, a peer-reviewed journal focusing on the latest innovations, big ideas, and practical solutions for healthcare delivery transformation.
- NEJM Journal Watch, which helps clinicians efficiently understand medical developments to improve patient care and foster professional development.
As a result of this distribution agreement, Wolters Kluwer Health Learning, Research & Practice will account for NEJM Group digital subscription revenues and related costs. The agreement has a positive but immaterial impact on the consolidated earnings of the Wolters Kluwer group.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer Health provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
